WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Trump says he is open to restrictions on contraception before backing away from the statement
Baywatch star Jeremy Jackson's ex
Int'l horticultural expo attracts worldwide green fingers to Chengdu
Microsoft's AI chatbot will remember everything you do on a PC
King Charles returns to public duties after cancer diagnosis
Colombia's president says thousands of grenades and bullets have gone missing from army bases
Elvis' granddaughter Riley Keough fights Graceland estate auction
Eva Mendes gushes over 'my Cuban Papi' Ryan Gosling after he wears T